A biotech company we’ve been following for several years – on what has turned out to be a rollercoaster ride so far – is Corvus Pharmaceuticals (NASDAQ: CRVS).
They were pioneers in targeting the adenosine pathway with their adenosine A2A receptor antagonist, CPI–444, now known as ciforadenant.
So what’s new at Corvus? It turns out quite a lot.
At ASCO 2019, BSB caught up with Richard A Miller MD, Co-Founder, President, and CEO of Corvus Pharmaceuticals to learn more about their progress and importantly, where they’re headed.